Is there a gender gap in secondary prevention of coronary artery disease in Turkey? [Türkiye’de koroner arter hastalığından ikincil korunmada cinsiyet etkisi var mıdır?]
| Autor: | Koçyiğit, D, Tokgözoğlu, L, Kayıkçıoğlu, M, Altay, S, Aydoğdu, S, Barçın, C, Bostan, C, Çakmak, H.A, Çatakoğlu, A.B, Emet, S, Ergene, O, Kalkan, A.K, Kaya, B, Kaya, C, Kaymaz, C, Koylan, N, Kültürsay, H, Oğuz, A, Özpelit, E, Ünlü, S. |
|---|---|
| Přispěvatelé: | Ege Üniversitesi, Kardiyoloji |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: | |
| Popis: | PubMed ID: 30516526 Objective: It has been reported that women receive fewer preventive recommendations regarding pharmacological treatment, lifestyle modifications, and cardiac rehabilitation compared with men who have a similar risk profile. This study was an investigation of the impact of gender on cardiovascular risk profile and secondary prevention measures for coronary artery disease (CAD) in the Turkish population. Methods: Statistical analyses were based on the European Action on Secondary and Primary Prevention through Intervention to Reduce Events (EUROASPIRE)-IV cross-sectional survey data obtained from 17 centers in Turkey. Male and female patients, aged 18 to 80 years, who were hospitalized for a first or recurrent coronary event (coronary artery bypass graft, percutaneous coronary intervention, acute myocardial infarction, or acute myocardial ischemia) were eligible. Results: A total of 88 (19.7%) females and 358 males (80.3%) were included. At the time of the index event, the females were significantly older (p=0.003) and had received less formal education (p0.05). Conclusion: Achievement of ideal body weight, fasting blood glucose and blood pressure targets was lower in women despite similar reported medication use. This highlights the importance of the implementation of lifestyle measures and adherence to medications in women. © 2018 Turkish Society of Cardiology. Istanbul Üniversitesi The EUROASPIRE-IV Turkey study was unconditionally supported by AstraZeneca BioPharmaceuti-cal Company, Istanbul, Turkey. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|